- Home
- PRFX vs GCTK Comparison
PRFX vs GCTK Comparison
Compare PRFX & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRFX | GCTK |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.4M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PRFX | GCTK |
|---|---|---|
| Price | $1.96 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 329.5K | ★ 3.9M |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 31.22 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.09 |
| 52 Week High | $3.71 | $15.90 |
Technical Indicators
Market Signals| Indicator | PRFX | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 41.15 |
| Support Level | $1.80 | $0.64 |
| Resistance Level | $2.89 | $1.02 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 10.33 | 8.81 |
Price Performance
Historical ComparisonAbout PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.